Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Established cell cultures have been the predominant research models of osteosarcoma for decades, but the culture-related alterations that cell lines acquire over tens and sometimes hundreds of passages 220,221 led to the development of systems for propagating osteosarcoma tumours 220,221 by creating libraries of primary tumour cell cultures and patient-derived xenografts (PDXs).”
From Osteosarcoma (2022) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, it has been shown that established cell lines do not capture disease heterogeneity across patients and hence are lacking in clinical relevance (Gillet et al., 2011; Yee et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Gillet et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Among those genes, ATP-binding cassette (ABC) transporters, a superfamily of 48 highly homologous members classified in seven subfamilies, have an important role in the pleiotropic mechanisms mediating MDR by exporting chemotherapeutic agents from the cell (14, 15).”
BackgroundSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Cited by
Items 201–300 of 476
Weeden, C. E., Holik, A. Z., Young, R. J., Ma, S. B., Garnier, J.-M., Fox, S. B., Antippa, P. N., Irving, L. B., Steinfort, D., Wright, G. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0174 · Cited by 25
“Cell lines are commonly used to test novel therapeutics, but do not often accurately model clinical samples, nor do they correlate with drug sensitivity in clinical trials (15, 16).”
BackgroundBreideband, L., Wächtershäuser, K. N., Hafa, L., Wieland, K., Frangakis, A. S., Stelzer, E. H. K., & Pampaloni, F. (2022) · Advanced Materials Technologies · doi:10.1002/admt.202200029 · Cited by 25
Tong, M., Zheng, W., Lu, X., Ao, L., Li, X., Guan, Q., Cai, H., Li, M., Yan, H., Guo, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5649 · Cited by 24
“However, findings of such studies can be hardly translated into clinical practice [10–14].”
Functional Genomic Characterization of Cancer Genomes
Howard, T. P., Vázquez, F., Tsherniak, A., Hong, A. L., Rinne, M. L., Aguirre, A. J., Boehm, J. S., & Hahn, W. C. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031070 · Cited by 26
“Cells grown in culture for extended periods of time tend to genomically resemble each other more than primary cancers from the same tissue, suggesting both clonal selection for growth on plastic and evolution due to a variety of pressures not present in vivo (Gillet et al. 2011).”
BackgroundGottesman, M. M., Robey, R. W., & Ambudkar, S. V. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.86 · Cited by 24
Pipiya, V. V., Gilazieva, Z. E., Issa, S. S., Rizvanov, A. A., & Solovyeva, V. V. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00237 · Cited by 23
Patient-derived xenografts: A platform for accelerating translational research in prostate cancer
Davies, A., Wang, Y. Z., & Zoubeidi, A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.013 · Cited by 27
“…generating cell lines yields major alterations in biological properties, including gain and loss of genetic information as well as modifications in invasive capabilities and the reliance on specific growth and survival pathways (Gillet et al., 2011; Hausser and Brenner, 2005; Daniel et al., 2009).”
BackgroundCybula, M., Wang, L., Wang, L., Drumond‐Bock, A. L., Moxley, K. M., Benbrook, D. M., Gunderson-Jackson, C., Ruiz-Echevarría, M. J., Bhattacharya, R., Mukherjee, P., et al. (2021) · Cancers · doi:10.3390/cancers13246288 · Cited by 23
“Long-established cancer cell lines and cell line-based xenograft models have long been the workhorse of cancer research; however, the marked differences between in vitro cell culture conditions and the in vivo tumor environment raise concerns that these models lack proper representation of actual human tumors [4,5].”
BackgroundAdvances of Osteosarcoma Models for Drug Discovery and Precision Medicine
Tan, L., Wang, Y., Hu, X., Du, G., Tang, X., & Min, L. (2023) · Biomolecules · doi:10.3390/biom13091362 · Cited by 26
“Despite their easy manipulation, adaptability for global studies, and suitability for highthroughput applications, their questionable accuracy in reflecting clinical samples is a persistent concern [25,26].”
BackgroundStein, A. P., Saha, S., Liu, C., Hartig, G. K., Lambert, P. F., & Kimple, R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100995 · Cited by 22
“demonstrated through genetic analyses that no correlation existed between patient tumors and established cancer cell lines, and in fact the cell lines bore greater resemblance to each other than to clinical samples [23].”
Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies
Stein, A. P., Swick, A. D., Smith, M. A., Blitzer, G. C., Yang, R., Saha, S., Harari, P. M., Lambert, P. F., Liu, C., & Kimple, R. J. (2015) · Cancer Medicine · doi:10.1002/cam4.387 · Cited by 23
“Several groups have questioned the clinical relevance of cell lines and cell line xenografts since tumors generated from immortalized lines may not perfectly represent the primary tumor [41–44].”
BackgroundA novel patient-derived xenograft model for claudin-low triple-negative breast cancer
Matossian, M. D., Burks, H. E., Bowles, A. C., Elliott, S. G., Hoang, V. T., Sabol, R. A., Pashos, N. C., O’Donnell, B. T., Miller, K. S., Wahba, B., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4685-2 · Cited by 24
“Passaging of immortalized cell lines results in the introduction of irreversible alterations in genetic information and behavioral characteristics [16].”
BackgroundEhlen, L., Arndt, J., Treue, D., Bischoff, P., Loch, F. N., Hahn, E. M., Kotsch, K., Klauschen, F., Beyer, K., Margonis, G. A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06929-8 · Cited by 22
Tucker, E. R., George, S. L., Angelini, P., Bruna, A., & Chesler, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040248 · Cited by 25
“However, it is widely acknowledged that these lines have grown in artificial cell culture conditions and consequently drifted so that they no longer resemble the originating tumour, and therefore they have limited clinical predictive power [20].”
BackgroundMicrofabricated polymeric vessel mimetics for 3-D cancer cell culture
Jaeger, A., Das, C. K., Morgan, N. Y., Pursley, R. H., McQueen, P. G., Hall, M. D., Pohida, T. J., & Gottesman, M. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.013 · Cited by 24
“These differences have been attributed to discrepancies between two-dimensional (2-D) culture and the threedimensional (3-D) tumor environment, including substrate architecture and rigidity [1,9], the effect of neighboring, non-malignant cells in vivo, including vasculature and immune cells [10], the nature of cell cl…”
BackgroundCheung, P. F., Yip, C. W., Ng, L. W. C., Lo, K. W., Chow, C., Chan, K. F., Cheung, T. T., & Cheung, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0322-5 · Cited by 24
“is due to the changes in the biological properties of cancer cells during their adaptation to the in vitro culture conditions and long-term culture [4, 5].”
Li, Y., Sun, T., Chen, Z., Shao, Y., Huang, Y., & Zhou, Y. (2020) · Journal of Cancer · doi:10.7150/jca.40802 · Cited by 22
“However, accumulation of genetic aberrations of cancer cell lines often occurs with increasing passage numbers has limited their application [6,7].”
BackgroundThe contribution and perspectives of proteomics to uncover ovarian cancer tumor markers
de Carvalho, V. P., Grassi, M. L., Palma, C. D. S., Carrara, H. H. A., Faça, V. M., dos Reis, F. J. C., & Poersch, A. (2018) · Translational research · doi:10.1016/j.trsl.2018.11.001 · Cited by 23
Current status and perspectives of patient-derived rare cancer models
Kondo, T. (2020) · Human Cell · doi:10.1007/s13577-020-00391-1 · Cited by 21
3D Tumor Models for Breast Cancer: Whither We Are and What We Need
Balachander, G. M., Kotcherlakota, R., Nayak, B., Kedaria, D., Rangarajan, A., & Chatterjee, K. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00230 · Cited by 23
Alkan, A., Hofving, T., Angenete, E., & Yrlid, U. (2021) · Biomarker Research · doi:10.1186/s40364-021-00313-9 · Cited by 23
Ganjibakhsh, M., Aminishakib, P., Farzaneh, P., Karimi, A., Fazeli, S. A. S., Rajabi, M., Nasimian, A., Naini, F. B., Rahmati, H., Gohari, N. S., et al. (2013) · Europe PMC (PubMed Central) · Cited by 21
Wu, C., Lusvarghi, S., Wang, J.-C., Hsiao, S.-H., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010238 · Cited by 20
“At present, the development of multidrug resistance during the course of cancer treatment associated with the upregulation and overexpression of ABC drug transporters in cancer cells remains an unsolved problem in modern chemotherapy [3,4,41].”
BackgroundLong-term maintenance of patient-specific characteristics in tumoroids from six cancer indications
Paul, C. D., Yankaskas, C., Thakuri, P. S., Balhouse, B. N., Salen, S., Bullock, A., Beam, S., Chatman, A., Djikeng, S., Yang, X. J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-86979-9 · Cited by 20
Khurana, A., & Godugu, C. (2017) · Springer series in biomaterials science and engineering · doi:10.1007/978-981-10-6910-9_6 · Cited by 25
Preclinical Models of Brain Metastases in Breast Cancer
Knier, N. N., Pellizzari, S., Zhou, J., Foster, P. J., & Parsyan, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10030667 · Cited by 28
“A majority of the models are based on the use of the IBCC lines propagated through numerous passages, decreasing their utility to represent BC heterogeneity, unique characteristics of brain metastases, and our ability to draw generalizations for clinical applications [115,116].”
BackgroundAn Aptamer for Broad Cancer Targeting and Therapy
Gray, B. P., Song, X., Hsu, D. S., Kratschmer, C., Levy, M., Barry, A. P., & Sullenger, B. A. (2020) · Cancers · doi:10.3390/cancers12113217 · Cited by 21
“Although human tumor-derived cell lines are the most broadly used tissue culture models for cancer studies and remain extremely important and useful models, they do not always fully recapitulate the complexity of human tumors (reviewed in [26]) and often experience major changes in biology compared to their tumor of o…”
BackgroundOptimization of cell lines as tumour models by integrating multi-omics data
Zhao, N., Liu, Y., Wei, Y., Yan, Z., Zhang, Q., Wu, C., Chang, Z., & Xu, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw082 · Cited by 20
Wang, X., Cao, Y., Chen, S., Yang, X., Bian, J., & Huang, D. (2023) · Antioxidants · doi:10.3390/antiox12010204 · Cited by 19
“The divergent microenvironments from real tissue result in different cellular behaviors, such as proliferation rate [7], gene expressions [8], and drug resistance [9].”
BackgroundProteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
Casado, P., & Cutillas, P. R. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100517 · Cited by 19
“survival showed that cell lines from different origins (including AML) were more similar between them than to the primary tumor cells that they were supposed to model (90).”
ResultShort-form Ron is a novel determinant of ovarian cancer initiation and progression
Moxley, K. M., Wang, L., Welm, A. L., & Bieniasz, M. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.109 · Cited by 19
“It is well recognized that cell lines only partially recapitulate the genetic features and heterogeneity of ovarian tumors in patients [13].”
BackgroundPATIENT-DERIVED XENOGRAFTS AS A PRECLINICAL MODEL FOR BONE SARCOMAS
Meohas, W., Granato, R. A., Guimaräes, J. A. M., Dias, R. B., Fortuna-Costa, A., & Duarte, M. E. L. (2018) · Acta Ortopédica Brasileira · doi:10.1590/1413-785220182602186998 · Cited by 20
Developing preclinical models of neuroblastoma: driving therapeutic testing
Ornell, K. J., & Coburn, J. M. (2019) · BMC Biomedical Engineering · doi:10.1186/s42490-019-0034-8 · Cited by 21
“However, growth with serum has been demonstrated to lead to cellular differentiation and genetic changes, causing the cells to stop mimicking their original clinical phenotype and increase their drug sensitivity [112, 113].”
BackgroundStojković, S., Podolski-Renić, A., Dinić, J., Stanković, T., Banković, J., Hadžić, S., Paunović, V., Isaković, A., Tanić, N., & Pešić, M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.018 · Cited by 20
Generation of Cisplatin-Resistant Ovarian Cancer Cell Lines
Nikounezhad, N., Nakhjavani, M., & Shirazi, F. H. (2016) · Iranian journal of pharmaceutical sciences · doi:10.22034/ijps.2016.19001 · Cited by 22
“The establishment of chemoresistant cancer cell lines might be one of the useful model systems to study molecular mechanisms leading to cancer drug resistance [17].”
BackgroundCancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
Kim, H. S., Sung, Y.-J., & Paik, S. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2015.56.5.1186 · Cited by 19
“Specifically, cell lines are prone to artificial selection during prolonged culturing, which skews gene expression programs, including those related to multidrug resistance.(29) One study that compared mutations, changes in DNA copy number, and mRNA expression profiles found significant differences between ovarian can…”
BackgroundMechanisms of Resistance Against Cancer Therapeutic Drugs
Chatterjee, S., Damle, S. G., & Sharma, A. K. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666141126123952 · Cited by 18
Monitoring Trastuzumab Resistance and Cardiotoxicity
Dokmanovic, M., & Wu, W. J. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.03.006 · Cited by 18
The Importance and Clinical Relevance of Surfaces in Tissue Culture
Hickman, G. J., Boocock, D. J., Pockley, A. G., & Perry, C. C. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00403 · Cited by 19
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
Aaltonen, K. E., Radke, K., Adamska, A., Seger, A., Mañas, A., & Bexell, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1085270 · Cited by 21
Taher, L., Beck, J., Liu, W., Roolf, C., Soller, J. T., Rütgen, B. C., Hammer, S. E., Chodisetti, M., Sender, S., Sterenczak, K. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23207-7 · Cited by 17
Mouse models of endocrine tumors
Gahete, M. D., Jiménez‐Vacas, J. M., Alors‐Pérez, E., Herrero‐Aguayo, V., Fuentes-Fayos, A. C., Pedraza‐Arévalo, S., Castano, J. P., & Luque, R. M. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0571 · Cited by 18
Organotypic Modeling of the Tumor Landscape
Haykal, M. M., Nahmias, C., Varon, C., & Martin, O. C. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606039 · Cited by 19
Paschke, L., Jopek, K., Szyszka, M., Tyczewska, M., Ziółkowska, A., Ruciński, M., & Malendowicz, L. K. (2016) · BioMed Research International · doi:10.1155/2016/6963582 · Cited by 19
Leiting, J. L., Hernandez, M. C., Yang, L., Bergquist, J. R., Ivanics, T., Graham, R. P., & Truty, M. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-42470-w · Cited by 17
Lei, Z., Teng, Q., Gupta, P., Zhang, W., Narayanan, S., Yang, D., Wurpel, J. N. D., Fan, Y., & Chen, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.640957 · Cited by 19
Exploring Nanoemulsions for Prostate Cancer Therapy
Srivastava, S., Haider, M. F., Ahmad, A., Ahmad, U., Arif, M., & Ali, A. (2021) · Drug Research · doi:10.1055/a-1518-6606 · Cited by 19
“The Association of DHA with paclitaxel leads to a weak decrease in P-GP and ABC transporters [57].”
BackgroundOrganoid: Next-Generation Modeling of Cancer Research and Drug Development
Liu, J., Huang, X., Huang, L., Huang, J., Liang, D., Liao, L., Deng, Y., Zhang, L., Zhang, B., & Tang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.826613 · Cited by 16
“Cancer cell lines are simple in culture conditions and easy to maintain, have broad utility and lower reagent costs (17), and can proliferate indefinitely in vitro but have more external mutations during culture, such as acquisition and loss of genetic information and altered growth and invasiveness (18, 19).”
BackgroundCunnea, P., & Stronach, E. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00081 · Cited by 16
“However, one study revealed no major gene expression profile differences in OVCAR-5 cells grown in either 2D or 3D culture (50).”
BackgroundPicca, F., Giannotta, C., Tao, J., Giordanengo, L., Munir, H., Botta, V., Merlini, A., Mogavero, A., Garbo, E., Poletto, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910823 · Cited by 17
Molecular and clinical implementations of ovarian cancer mouse avatar models.
Zayed, A. A., Mandrekar, S. J., & Haluska, P. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.04.01 · Cited by 17
“For example, cells’ genetic information, growth patterns, invasion behaviors, and accompanying cellular population all acquire various alterations in order to adapt to such new environment (5).”
BackgroundBeyond precision surgery: Molecularly motivated precision care for gastric cancer
Choi, Y. Y., & Cheong, J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.02.013 · Cited by 14
Ahmad, G., Gattacecca, F., Sadda, R. R. E., Botchkina, G. I., Ojima, I., Egan, J., & Amiji, M. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2349-x · Cited by 17
“As a result, these cancer cell lines have little or poor correlation with the original clinical samples and hence their use for the study of genomic alterations, discovery of clinically relevant molecular targets, and anticancer drug development is compromised (11).”
BackgroundEffects of phytoestrogens on the activity and growth of primary breast cancer cells ex vivo
Chen, F., & Chien, M. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13982 · Cited by 19
“cell lines may be unable to adequately represent the complexity of these diseases.(21,22) In addition, limited”
BackgroundKinomics platform using GBM tissue identifies BTK as being associated with higher patient survival
Shboul, S. A., Curran, O. E., Alfaro, J. A., Lickiss, F., Nita, E., Kowalski, J., Naji, F., Nenutil, R., Ball, K. L., Krejčíř, R., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202101054 · Cited by 15
“larly, GBM cell lines cluster together, separately from the GBM tissue samples, with up-regulation of survival-related genes in the cell lines (65).”
BackgroundAssociation of stem cell marker expression pattern and survival in human biliary tract cancer
Kemmerling, R., Alinger, B., Dietze, O., Bösmüller, H.-C., Ocker, M., Wolkersdörfer, G. W., Berr, F., Neureiter, D., & Kiesslich, T. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1477 · Cited by 14
Individual patient oesophageal cancer 3D models for tailored treatment
Saunders, J. H., Onion, D., Collier, P., Dorrington, M. S., Argent, R. H., Clarke, P. A., Reece-Smith, A. M., Parsons, S. L., & Grabowska, A. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12500 · Cited by 16
“[34] Organotypic modelling, [35, 36] xenografts, [37, 38] and spheroid culture [16, 39] have all been attempted to study oesophageal cancer in a more relevant setting, and in some cases using cancer cells taken directly from the patient.”
BackgroundSchunselaar, L. M., Quispel-Janssen, J. M. M. F., Kim, Y., Alifrangis, C., Zwart, W. T., Baas, P., & Neefjes, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1345 · Cited by 14
Tischfield, D. J., Ackerman, D., Noji, M., Chen, J. X., Johnson, O., Perkons, N. R., Nadolski, G., Hunt, S. J., Soulen, M. C., Furth, E. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47104-9 · Cited by 15
Adhikari, P., Nagesh, P. K. B., Alharthi, F., Chauhan, S. C., Jaggi, M., Yallapu, M. M., & Pradhan, P. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.006422 · Cited by 14
Koras, K., Kizling, E., Juraeva, D., Staub, E., & Szczurek, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94564-z · Cited by 25
Song, H., Lee, C., Kim, S. T., Kim, S. Y., Kim, N. K. D., Jang, J., Kang, M., Jang, H., Ahn, S., Kim, S.-H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7526 · Cited by 14
“Although cell line models are less costly than PDX models, they cannot accurately reflect the heterogeneity of primary tumors [14].”
BackgroundZloza, A., Palucka, K., Coussens, L. M., Gotwals, P. J., Headley, M. B., Jaffee, E. M., Lund, A. W., Sharpe, A. H., Sznol, M., Wainwright, D. A., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0278-6 · Cited by 16
“The advantage of the PDX model system over cell line-derived tumor models is the ability to model diverse tumor types directly from patients and potential retention of non-tumor cells from the human TME [11].”
BackgroundEstablishment of Patient-Derived Tumor Xenograft Models of High-Risk Endometrial Cancer
Zhu, M., Jia, N., Nie, Y.-Y., Chen, J., Jiang, Y., Lv, T., Li, Y., Yao, L., & Feng, W. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001365 · Cited by 15
Mandrup, O. A., Lykkemark, S., & Kristensen, P. K. (2017) · Scientific Reports · doi:10.1038/srep42230 · Cited by 13
“In this regard Gillet et al. have previously shown that cultured cancer cell lines resemble each other more than the clinical sample regardless of tissue of origin 35 .”
Foksiński, M., Zarakowska, E., Gackowski, D., Skonieczna, M., Gajda, K., Hudy, D., Szpila, A., Białkowski, K., Starczak, M., Wołowiec, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188856 · Cited by 15
Advantages of the avian model for human ovarian cancer
Bernardo, A. D. M., Þorsteinsdóttir, S., & Mummery, C. L. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.619 · Cited by 14
“Immortalized normal ovarian surface and/or Fallopian tube epithelia constitute promising alternatives, since they may be genetically modified and cultured for long periods, although they do not mimic the initial stages of the disease (53).”
In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles
Abreu, T. R., Biscaia-Caleiras, M., Gonçalves, N., Fonseca, N. A., & Moreira, J. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_12 · Cited by 18
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Culture Models to Define Key Mediators of Cancer Matrix Remodeling
Fuller, E. S., & Howell, V. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00057 · Cited by 20
“Other substrates such as collagen gels (40), polyhydroxyethylmethacrylate coated plastics (22), algimatrix, and geltrex are also used to model ECM (16).”
BackgroundMethodInfluentialSun, Y. E., & Liu, Q. (2015) · BioMed Research International · doi:10.1155/2015/901303 · Cited by 11
“This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.”
MethodBeesley, A. H., Firth, M. J., Anderson, D. R., Samuels, A. L., Ford, J., & Kees, U. R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3852 · Cited by 15
“Whilst the adequacy of cell lines to accurately reflect in vivo disease continues to be a matter of considerable debate (36), we have previously demonstrated that our panel demonstrates critical features of the primary disease, particularly in relation to drug-sensitivity profiles and patterns of growth (20, 37), and…”
BackgroundPerry, J. R., Ashford, B., Thind, A. S., Gauthier, M.-E., Minaei, E., Major, G. S., Iyer, N. G., Gupta, R., Clark, J. R., & Ranson, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249536 · Cited by 14
Harada, Y., Sato, A., Nakamura, H., Kai, K., Kitamura, S., Nakamura, T., Kurihara, Y., Ikeda, S., Sueoka, E., Kimura, S. H., et al. (2023) · BMC Cancer · doi:10.1186/s12885-022-10428-3 · Cited by 13
“This is likely due to changes in genetic profiles and gene expressions during the process of cell line establishment [25, 26].”
BackgroundZhang, J., Jia, J., Zhu, F., Ma, X., Han, B., Wei, X., Tan, C., Jiang, Y., & Chen, Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb25165e · Cited by 13
Hameed, R., Khan, A., Khan, S., & Perveen, S. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666181009163014 · Cited by 13
Flørenes, V. A., Karlsen, K. F., McFadden, E., Bergheim, I. R., Nygaard, V., Nygård, V., Farstad, I. N., Øy, G. F., Emilsen, E., Fleten, K. G., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.001 · Cited by 14
GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report
Patel, S. P., Kim, D. W., Lacey, C., & Hwu, P. (2016) · Medicine · doi:10.1097/md.0000000000002336 · Cited by 13
Establishment of gastric cancer organoid and its application in individualized therapy
Miao, X., Wang, C., Chai, C., Tang, H., Hu, J., Zhao, Z., Luo, W., Zhang, H., Zhu, K., Zhou, W., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13567 · Cited by 15
Richter, A., Roolf, C., Sekora, A., Knuebel, G., Krohn, S., Lange, S., Krebs, V., Schneider, B., Lakner, J., Wittke, C., et al. (2022) · Cells · doi:10.3390/cells11010150 · Cited by 11
“Still, cell line-based model systems possess only reduced translational potential; the results of in vitro experiments are hampered because of the limited ability to recapitulate the tumor cell biology, the clonal diversity of cancer samples or the specific tumor cell microenvironment [4,5].”
BackgroundApplication status and future prospects of the PDX model in lung cancer
Liu, W., Cui, Y., Zheng, X., Yu, K., & Sun, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098581 · Cited by 14
“In addition, pre-clinical models may experience gene alterations that cause gain/loss of genetic information and alter the seeding ability and the invasiveness of tumor cells (19).”
BackgroundMaugeri‐Saccà, M., Barba, M., Vici, P., Pizzuti, L., Sergi, D., Catenaro, T., Lauro, L. D., Mottolese, M., Santini, D., Milella, M. S., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.004 · Cited by 13
Piccoli, M., Ghiroldi, A., Monasky, M. M., Cirillo, F., Ciconte, G., Pappone, C., & Anastasia, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190103120725 · Cited by 11
Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
Hasbum, A., Karabulut, O., Reyes, R. E., Ricci, C., Franchi, A., Danti, S., & Chew, S. A. (2022) · Cancers · doi:10.3390/cancers14102503 · Cited by 12
Ma, Y., Lin, Z., Fallon, J. K., Zhao, Q., LIU, D., Wang, Y., & Liu, F. (2015) · Oncology Reports · doi:10.3892/or.2015.4265 · Cited by 11
“Its value, however, is limited due to its lack of relevance to clinical samples (3).”
BackgroundButti, R., Kapse, P., Bhadauriya, G., Ahmad, S., Chaubal, R., Parab, P. A., Kadam, R., Mahapatra, S. R., Shet, T. M., Dutt, A., et al. (2023) · Oncology Reports · doi:10.3892/or.2023.8536 · Cited by 10
“…1* , GARIMA BHADAURIYA 1* , SUHAIL AHMAD 2,3 , ROHAN CHAUBAL 3‑5 , PALLAVI PARAB 3,6 , RASIKA KADAM 4,6 , SOUMYA S. MAHAPATRA 7 , TANUJA SHET 3,8 , AMIT DUTT 2,3 , SUDEEP GUPTA 3,4,6 and GOPAL C. KUNDU 1,7,9 models acquire irreversible genetic and behavioral changes upon serial passaging (6,7).”
Ghini, V., Sorbi, F., Fambrini, M., & Magherini, F. (2024) · Cells · doi:10.3390/cells13080661 · Cited by 14
Failure to progress: breast and prostate cancer cell lines in developing targeted therapies
James, C., Whitehead, A., Plummer, J., Thompson, R. K., & Badal, S. A. M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10202-w · Cited by 12
“Particularly, cell lines expand our understanding of pharmacological processes, like drug sensitivity and resistance in cancer treatment [136].”
Shih, M., Lawal, B., Cheng, S., Olugbodi, J. O., Babalghith, A. O., Ho, C., Cavalu, S. D., Batiha, G. E., Albogami, S. M., Alotaibi, S. S., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.923503 · Cited by 9
“Scientific evidence has indicated that the expression of several oncogenic genes is associated with drug resistance in various cancers (Gillet et al., 2011).”
BackgroundBhadury, J., Einarsdottir, B. O., Podraza-Farhanieh, A., Bagge, R. O., Stierner, U. K., Ny, L., López, M. D., & Nilsson, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8181 · Cited by 14
“However, cell lines grown in continuous culture adapt to culture conditions, which could contribute to false positive responses to small molecule inhibition in vitro and in vivo [9, 10].”
BackgroundExperimental Metastasis: Modeling and Analysis
Malek, A. (2013) · Springer Netherlands · doi:10.1007/978-94-007-7835-1 · Cited by 11
High-Content Analysis with Cellular and Tissue Systems Biology
Gough, A., Lezon, T. R., Faeder, J. R., Chennubhotla, C., Murphy, R. F., Critchley-Thorne, R. J., & Taylor, D. L. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00025-1 · Cited by 11
Editor’s inaugural issue foreword: perspectives on translational and clinical research
Heger, M. (2015) · Journal of Clinical and Translational Research · doi:10.18053/jctres.201501.005 · Cited by 11
“On top of that, a considerable fraction of human cancer cell lines used in animal models genotypically and phenotypically resemble each other more than the tumor from which they originated [10], although exceptions do exist [11, 12].”
BackgroundEndometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
Tanaka, T., Nishie, R., Ueda, S., Miyamoto, S., Hashida, S., Konishi, H., Terada, S., Kogata, Y., Sasaki, H., Tsunetoh, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092606 · Cited by 11
“Established cell lines have been used for cancer research of many types of cancer, but these cells cannot simulate the heterogeneity of primary tumors [34].”
Hong, Y., Kim, N., Li, C., Jeong, E., & Yoon, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.055 · Cited by 10
Aghababazadeh, F. A., Lu, P., & Fridley, B. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-50936-0 · Cited by 10
Dalin, S., Grauman-Boss, B., Lauffenburger, D. A., & Hemann, M. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-09319-1 · Cited by 9
Obreque, J., Vergara-Gómez, L., Venegas, N., Weber, H. L., Owen, G. I., Pérez, P. E., Leal, P., Roa, J. C., & Bizama, C. (2023) · Biological Research · doi:10.1186/s40659-023-00476-9 · Cited by 11
Loperamide, an antidiarrheal agent, induces apoptosis and DNA damage in leukemia cells
He, X., Zhu, L., Li, S., Chen, Z., & Zhao, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7435 · Cited by 10
“However, gene aberrations in cancer cell lines occurring with increasing passage number has led to misrepresentative clinical scenarios, and thus limits their clinical correlation (38,39).”
Matossian, M. D., Giardina, A. A., Wright, M. K., Elliott, S. G., Loch, M. M., Nguyen, K., Zea, A. H., Lau, F. H., Moroz, K., Riker, A. I., et al. (2020) · Women s Health Reports · doi:10.1089/whr.2020.0037 · Cited by 9
“for years results in the introduction of irreversible alterations in genetic information and behavioral characteristics that were not present in the original tumor.(25) Matossian, et al.”
Background
Metadata
- Authors
- Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., & Gottesman, M. M.
- Affiliations
- National Cancer Institute (UA)
- National Institutes of Health (US)
- Biophase Systems, Fremont, CA 94539;
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-11-08
- Volume
- 108
- Issue
- 46
- Pages
- 18708-18713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3219108
- OpenAlex
- W2018044006
- Cited by
- 477
- References
- 46
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 43 · 2022: 28 · 2021: 34 · 2020: 41 · 2019: 45 · 2018: 33 · 2017: 46 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 29 · 2012: 16
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Georgetown University
- Karolinska Institutet
- National Institutes of Health
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Cancer Institute (NCI-60)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cancer cell lines, multidrug resistance, drug resistance mechanisms, xenografts, 3D cell culture, gene expression profiles, in vitro tumor model, tumor microenvironment
- MeSH terms
- Antineoplastic Agents, Cell Survival, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Ovary, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Cell Line, Tumor, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.